$MDNAF News

Here's Why We're Watching Medicenna Therapeutics' (TSE:MDNA) Cash Burn Situation

Medicenna Therapeutics Announces Key Program Updates and 2026 Outlook

Dr. Fahar Merchant acquires shares of Medicenna

Medicenna Updates MDNA11 Clinical Trial Results at the ESMO-IO Congress 2025, Further Bolstering its Anti-Tumor Activity in Advanced Solid Tumors

Medicenna Therapeutics to Host a Live Webinar with Q&A to Discuss Updated MDNA11 Clinical Data

Medicenna Therapeutics Reports Second Quarter Fiscal 2026 Financial Results and Provides a Corporate Update

Medicenna's MDNA-11 to Be Tested With Immunotherapies in Italian Melanoma Trial

Medicenna and Fondazione Melanoma Onlus Collaborate to Advance MDNA11 Before First-Line Therapy in a Randomized Neoadjuvant Combination Trial, “NEO-CYT”, in High-Risk, Surgically Resectable Stage III Melanoma

Mismatch Repair Deficiency Market Forecasts Strong Expansion During the Forecast Period (2025-2034) Driven by Rising Diagnostics and Immuno-Oncology Advances | DelveInsight

Updated MDNA11 Clinical Data from the ABILITY-1 Study to be Presented at the European Society for Medical Oncology (ESMO) Immuno-Oncology Congress 2025

3 TSX Penny Stocks With Market Caps Under CA$90M

ROTH to Host 4th Annual Healthcare Opportunities Conference on October 9 in New York City

Medicenna Therapeutics to Participate in the ROTH 4th Annual Healthcare Opportunities Conference

Medicenna Announces Results of Annual Meeting of Shareholders

Medicenna Therapeutics (MDNAF) Upgraded to Buy: Here's What You Should Know

Medicenna to Participate at the H.C. Wainwright 27th Annual Global Investment Conference

Medicenna Therapeutics Reports First Quarter Fiscal 2026 Financial Results and Operational Highlights

Medicenna Strengthens Intellectual Property Portfolio with Five Patents Granted for its IL-2 and IL-4 Superkines

TSX Opportunities: Haivision Systems And Two Other Promising Penny Stocks

Medicenna Fiscal Year Net Loss Decreases, Beats Forecast